{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:18:50Z","timestamp":1779322730084,"version":"3.51.4"},"reference-count":126,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of chronic myeloid leukemia (CML), but patients still experience treatment\u2010limiting toxicities or therapeutic failure. To investigate the real\u2010world use and outcomes of imatinib in patients with CML in Australia, a retrospective cohort study of patients with CML commencing imatinib (2001\u20132018) was conducted across two sites. Prescribing patterns, tolerability outcomes, and survival and molecular response were evaluated. 86 patients received 89 imatinib treatments. Dose modifications were frequently observed (12\u2010month rate of 58%). At last follow\u2010up, 62 patients (5\u2010year rate of 55%) had permanently discontinued imatinib treatment, of which 44 switched to another TKI (5\u2010year rate of 46%). Within 3\u00a0months of starting imatinib, 43% (95% CI, 32%\u201353%) of patients experienced imatinib\u2010related grade \u22653 adverse drug reactions (ADRs). Higher comorbidity score, lower body weight, higher imatinib starting dose, and Middle Eastern or North African ancestry were associated with a higher risk of grade \u22653 ADR occurrence on multivariable analysis (MVA). Estimated overall survival and event\u2010free survival rates at 3\u2009years were 97% (95% CI, 92%\u2013100%) and 81% (95% CI, 72%\u201392%), respectively. Cumulative incidence of major molecular response (MMR) at 3\u2009years was 63% (95% CI, 50%\u201373%). On MVA, imatinib starting dose, ELTS score, <jats:italic>BCR\u2010ABL1<\/jats:italic> transcript type, pre\u2010existing pulmonary disease, and potential drug\u2013drug interactions were predictive of MMR. In conclusion, imatinib induced deep molecular responses that translated to good survival outcomes in a real\u2010world setting, but was associated with a higher incidence of ADRs, dose modifications and treatment discontinuations than in clinical trials.<\/jats:p>","DOI":"10.1002\/prp2.1005","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T06:15:17Z","timestamp":1663222517000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real\u2010world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2575-7910","authenticated-orcid":false,"given":"Josephine A.","family":"Adattini","sequence":"first","affiliation":[{"name":"Sydney Pharmacy School The University of Sydney  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9567-0127","authenticated-orcid":false,"given":"Annette S.","family":"Gross","sequence":"additional","affiliation":[{"name":"Sydney Pharmacy School The University of Sydney  Sydney New South Wales Australia"},{"name":"Clinical Pharmacology Modelling &amp; Simulation GlaxoSmithKline R &amp;D  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3725-3397","authenticated-orcid":false,"given":"Nicole","family":"Wong Doo","sequence":"additional","affiliation":[{"name":"Concord Cancer Centre Concord Repatriation General Hospital  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4674-0242","authenticated-orcid":false,"given":"Andrew J.","family":"McLachlan","sequence":"additional","affiliation":[{"name":"Sydney Pharmacy School The University of Sydney  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001329"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1126.1126"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201010\u2010462291"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100842\u20109"},{"key":"e_1_2_12_8_1","volume-title":"Enrolments in Cancer Clinical Trials as a Proportion of Cancer Incidence","author":"Cancer Institute NSW"},{"key":"e_1_2_12_9_1","volume-title":"Framework for FDA's Real\u2010World Evidence Program","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010018\u20100805\u2010y"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.8\u20106\u2010579"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4186"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2055"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/23.4.278"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2006.07.001"},{"issue":"4","key":"e_1_2_12_16_1","first-page":"e85","article-title":"Classification of Canadian immigrants into visible minority groups using country of birth and mother tongue","volume":"7","author":"Rezai MR","year":"2013","journal-title":"Open Med"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021\u20109681(87)90171\u20108"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0047"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds228"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.261"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_12_24_1","volume-title":"Requirements for Adverse Drug Reaction Reporting","author":"World Health Organization","year":"1975"},{"key":"e_1_2_12_25_1","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0","author":"National Cancer Institute (U.S.)","year":"2017"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517\u20106161.1972.tb00899.x"},{"key":"e_1_2_12_28_1","volume-title":"Topics in Biostatistics Methods in Molecular Biology","author":"Nick TG","year":"2017"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft355"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.115.017719"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(16)30223\u20106"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.359"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705727"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4264"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1739"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.2307\/2335582"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.36"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100776\u20102"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201007\u2010294330"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v045.i03"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a117592"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7048"},{"key":"e_1_2_12_46_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2020"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15537"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.174953"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201006\u2010511592"},{"key":"e_1_2_12_52_1","unstructured":"Novartis Pharmaceuticals Corporation.Efficacy of 400\u2009mg versus 800\u2009mg imatinib in chronic myeloid leukemia in chronic phase patients \u2010 TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity). Accessed September 10 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00124748"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.49.9020"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.15.8154"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23691"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.32.0598"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25342"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(10)70233\u20103"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24120"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.06.018"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205054"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.68.2914"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(18)30192\u2010X"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.48.5797"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201002\u2010483750"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.02.004"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3724"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903479299"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102007\u201010\u2010116475"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201007\u2010036012"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000004"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12007"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010016\u20100494\u20100"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604355"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.045666"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.186"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.885515"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010009\u20100621\u2010z"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.07.014"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349\u20107006.2010.01643.x"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010015\u20102905\u20106"},{"key":"e_1_2_12_84_1","doi-asserted-by":"crossref","unstructured":"AdattiniJA AdiwidjajaJ GrossAS McLachlanAJ.Application of physiologically\u2010based pharmacokinetic modelling to understand real\u2010world outcomes in patients receiving imatinib for chronic myeloid leukaemia. Submitted under Review.2022.","DOI":"10.1002\/prp2.1082"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185\u2010019\u201002805\u20109"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13852"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/ftd.0000000000000440"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2010.79"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2017.09.09"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.866663"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185\u2010017\u20102353\u20107"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201001\u2010617993"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.2296.2296"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.2751.2751"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.2887.2887"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000566212.35482.b2"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.96"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217743565"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/ped.12382"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201006\u20100773"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488408785747656"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.048017"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601152"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1097\/ftd.0000000000000084"},{"key":"e_1_2_12_106_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010016\u20102038\u20109"},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S237467"},{"key":"e_1_2_12_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010018\u20100136\u20107"},{"key":"e_1_2_12_109_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.170035"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201099\u2010117409"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.597.597"},{"key":"e_1_2_12_112_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.009134"},{"key":"e_1_2_12_113_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.096537"},{"key":"e_1_2_12_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201010\u2010674242"},{"key":"e_1_2_12_115_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24774"},{"key":"e_1_2_12_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12597"},{"key":"e_1_2_12_117_1","doi-asserted-by":"publisher","DOI":"10.35248\/2167\u20100501.19.8.263"},{"key":"e_1_2_12_118_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102003\u201001\u20100025"},{"key":"e_1_2_12_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102003\u201011\u20103800"},{"key":"e_1_2_12_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102007\u201008\u2010103499"},{"key":"e_1_2_12_121_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102008\u201006\u2010161737"},{"key":"e_1_2_12_122_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010010\u20100910\u20108"},{"key":"e_1_2_12_123_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12618"},{"key":"e_1_2_12_124_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.206797"},{"key":"e_1_2_12_125_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010016\u20102839\u2010z"},{"key":"e_1_2_12_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2274"},{"key":"e_1_2_12_127_1","volume-title":"Cancer Data in Australia","author":"Australian Institute of Health and Welfare","year":"2020"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.1005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.1005","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.1005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T03:31:02Z","timestamp":1692588662000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.1005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":126,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1002\/prp2.1005"],"URL":"https:\/\/doi.org\/10.1002\/prp2.1005","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"2022-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01005"}}